NASDAQ:KMDA Kamada (KMDA) Stock Forecast, Price & News $4.84 -0.14 (-2.81%) (As of 11:09 AM ET) Add Compare Share Share Today's Range$4.81▼$4.9350-Day Range$4.34▼$5.4052-Week Range$3.72▼$5.72Volume12,025 shsAverage Volume35,888 shsMarket Capitalization$216.93 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Kamada MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside124.0% Upside$11.00 Price TargetShort InterestHealthy0.01% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.45Based on 26 Articles This WeekInsider TradingN/AProj. Earnings Growth100.00%From $0.09 to $0.18 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.66 out of 5 starsMedical Sector94th out of 1,006 stocksPharmaceutical Preparations Industry33rd out of 492 stocks 3.5 Analyst's Opinion Consensus RatingKamada has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, Kamada has a forecasted upside of 124.0% from its current price of $4.91.Amount of Analyst CoverageKamada has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.01% of the float of Kamada has been sold short.Short Interest Ratio / Days to CoverKamada has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kamada has recently decreased by 60.58%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldKamada does not currently pay a dividend.Dividend GrowthKamada does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KMDA. Previous Next 3.0 News and Social Media Coverage News SentimentKamada has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 26 news articles for Kamada this week, compared to 3 articles on an average week.Search Interest5 people have searched for KMDA on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows2 people have added Kamada to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kamada insiders have not sold or bought any company stock.Percentage Held by Insiders36.10% of the stock of Kamada is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.29% of the stock of Kamada is held by institutions. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Kamada are expected to grow by 100.00% in the coming year, from $0.09 to $0.18 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kamada is -98.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kamada is -98.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKamada has a P/B Ratio of 1.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Kamada (NASDAQ:KMDA) StockKamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. It operates through the Proprietary Products and Distribution segments. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the drug products in Israel, which are manufactured by third parties. The company was founded by David Tsur and Ralf Hahn on December 13, 1990 and is headquartered in Rehovot, Israel.Read More Receive KMDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kamada and its competitors with MarketBeat's FREE daily newsletter. Email Address KMDA Stock News HeadlinesMay 31, 2023 | americanbankingnews.comFY2024 EPS Estimates for Kamada Ltd. (NASDAQ:KMDA) Lowered by AnalystMay 26, 2023 | finance.yahoo.comKMDA: 1Q23 Revenues of $30.7 Million; Continue to Expect 2023 Revenues of $138 Million to $146 Million…May 31, 2023 | Edge On The Street (Ad)The Ignored EV Story Few Investors Know AboutLithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain.May 26, 2023 | americanbankingnews.comKamada Ltd. (NASDAQ:KMDA) Forecasted to Post Q3 2023 Earnings of $0.04 Per ShareMay 25, 2023 | msn.comHC Wainwright & Co. Reiterates Kamada (KMDA) Buy RecommendationMay 25, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Kamada (NASDAQ:KMDA)May 24, 2023 | marketwatch.comKamada Shares Touch 52-Week High Amid Guidance, Funding Deal >KMDAMay 24, 2023 | finance.yahoo.comKamada Reports Strong First Quarter 2023 Financial Results; Reiterates Revenue and Profitability GuidanceMay 31, 2023 | Edge On The Street (Ad)146 Pounds of Graphite Needed for Each EVGraphite - not lithium - is the largest component of lithium-ion batteries used in electric vehicles. That's why 97 more graphite mines will be needed by 2035 just to keep up with battery demand for the $7 trillion EV market.May 24, 2023 | msn.comKamada: Q1 Earnings InsightsMay 24, 2023 | apnews.comKamada: Q1 Earnings SnapshotMay 24, 2023 | msn.comKamada CFO Chaime Orlev withdraws resignationMay 24, 2023 | finance.yahoo.comKamada Announces $60 Million Private Placement with FIMI Opportunity FundsMay 24, 2023 | finance.yahoo.comKamada Announces Chief Financial Officer Chaime Orlev to Remain in Role and Appointment of Nir Livneh as Vice President, General Counsel and Corporate SecretaryMay 23, 2023 | markets.businessinsider.comHere's what Wall Street expects from Kamada's earningsMay 23, 2023 | msn.comKamada Q1 2023 Earnings PreviewMay 17, 2023 | marketwatch.comKamada Announces Receipt of Marketing Authorization for Glassia(R) for Treatment of Alpha-1 Antitrypsin Deficiency in SwitzerlandMay 17, 2023 | finance.yahoo.comKamada to Announce First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023May 16, 2023 | msn.comKamada Earnings PreviewMay 16, 2023 | msn.comMilan hopeful of beating Dortmund & Tottenham to Daichi Kamada free transferMay 16, 2023 | finance.yahoo.comKamada Announces Receipt of Marketing Authorization for Glassia® for Treatment of Alpha-1 Antitrypsin Deficiency in SwitzerlandMay 16, 2023 | americanbankingnews.comKamada (NASDAQ:KMDA) Now Covered by Analysts at StockNews.comMay 14, 2023 | msn.comFootball: Kamada nets in Frankfurt win as Kubo shines in SpainApril 22, 2023 | americanbankingnews.comKamada (NASDAQ:KMDA) Coverage Initiated by Analysts at StockNews.comApril 13, 2023 | uk.news.yahoo.comKamada to leave Eintracht Frankfurt at the end of the seasonApril 13, 2023 | usatoday.comDaichi Kamada set to leave Frankfurt at end of seasonApril 13, 2023 | americanbankingnews.comOrgenesis (NASDAQ:ORGS) vs. Kamada (NASDAQ:KMDA) Head to Head ContrastSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive KMDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kamada and its competitors with MarketBeat's FREE daily newsletter. Email Address KMDA Company Calendar Last Earnings3/15/2023Today5/30/2023Next Earnings (Estimated)8/16/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KMDA CUSIPN/A CIK1567529 Webwww.kamada.com Phone(728) 940-6472Fax972-8940-6473Employees355Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.00 High Stock Price Forecast$11.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+120.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.05) Trailing P/E RatioN/A Forward P/E Ratio55.33 P/E GrowthN/ANet Income$-2,320,000.00 Net Margins-1.74% Pretax Margin-1.72% Return on Equity8.15% Return on Assets4.49% Debt Debt-to-Equity Ratio0.07 Current Ratio1.90 Quick Ratio0.75 Sales & Book Value Annual Sales$129.34 million Price / Sales1.73 Cash Flow$0.02 per share Price / Cash Flow205.86 Book Value$3.93 per share Price / Book1.27Miscellaneous Outstanding Shares44,820,000Free Float28,640,000Market Cap$223.20 million OptionableNot Optionable Beta0.99 Key ExecutivesAmir LondonChief Executive OfficerEran NirChief Operating OfficerNaveh TovVP-Clinical Development & Medical DirectorNir LivnehSecretary, Vice President & General CounselBoris GorelikVP-Business Development & Strategic ProgramsKey CompetitorsFulcrum TherapeuticsNASDAQ:FULCAadi BioscienceNASDAQ:AADIXOMANASDAQ:XOMANature's Sunshine ProductsNASDAQ:NATRImmuneeringNASDAQ:IMRXView All CompetitorsInstitutional OwnershipRenaissance Technologies LLCSold 6,340 shares on 5/12/2023Ownership: 1.895%UBS Group AGBought 47,257 shares on 5/12/2023Ownership: 0.107%Acadian Asset Management LLCSold 32,452 shares on 5/11/2023Ownership: 1.441%Meitav Investment House Ltd.Sold 18,306 shares on 5/11/2023Ownership: 0.146%Altshuler Shaham LtdBought 353,046 shares on 5/9/2023Ownership: 0.788%View All Institutional Transactions KMDA Stock - Frequently Asked Questions Should I buy or sell Kamada stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KMDA shares. View KMDA analyst ratings or view top-rated stocks. What is Kamada's stock price forecast for 2023? 1 brokerages have issued 1-year price objectives for Kamada's stock. Their KMDA share price forecasts range from $11.00 to $11.00. On average, they predict the company's share price to reach $11.00 in the next year. This suggests a possible upside of 120.9% from the stock's current price. View analysts price targets for KMDA or view top-rated stocks among Wall Street analysts. How have KMDA shares performed in 2023? Kamada's stock was trading at $4.01 on January 1st, 2023. Since then, KMDA stock has increased by 24.2% and is now trading at $4.98. View the best growth stocks for 2023 here. Are investors shorting Kamada? Kamada saw a decline in short interest in May. As of May 15th, there was short interest totaling 5,400 shares, a decline of 60.6% from the April 30th total of 13,700 shares. Based on an average trading volume of 20,300 shares, the short-interest ratio is currently 0.3 days. Approximately 0.0% of the shares of the stock are sold short. View Kamada's Short Interest. When is Kamada's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 16th 2023. View our KMDA earnings forecast. How were Kamada's earnings last quarter? Kamada Ltd. (NASDAQ:KMDA) announced its earnings results on Wednesday, March, 15th. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.04. The biotechnology company had revenue of $45.44 million for the quarter, compared to analyst estimates of $44.64 million. Kamada had a positive trailing twelve-month return on equity of 8.15% and a negative net margin of 1.74%. What guidance has Kamada issued on next quarter's earnings? Kamada issued an update on its FY 2023 earnings guidance on Friday, May, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $138.00 million-$146.00 million, compared to the consensus revenue estimate of $141.36 million. What other stocks do shareholders of Kamada own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kamada investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), NIC (EGOV), Micron Technology (MU), Teva Pharmaceutical Industries (TEVA) and Aegean Marine Petroleum Network (ANW). What is Kamada's stock symbol? Kamada trades on the NASDAQ under the ticker symbol "KMDA." Who are Kamada's major shareholders? Kamada's stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.89%), Acadian Asset Management LLC (1.44%), Altshuler Shaham Ltd (0.79%), Meitav Investment House Ltd. (0.15%) and UBS Group AG (0.11%). How do I buy shares of Kamada? Shares of KMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Kamada's stock price today? One share of KMDA stock can currently be purchased for approximately $4.98. How much money does Kamada make? Kamada (NASDAQ:KMDA) has a market capitalization of $223.20 million and generates $129.34 million in revenue each year. The biotechnology company earns $-2,320,000.00 in net income (profit) each year or ($0.05) on an earnings per share basis. How many employees does Kamada have? The company employs 355 workers across the globe. How can I contact Kamada? Kamada's mailing address is 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402. The official website for the company is www.kamada.com. The biotechnology company can be reached via phone at (728) 940-6472, via email at ir@kamada.com, or via fax at 972-8940-6473. This page (NASDAQ:KMDA) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kamada Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.